March 29, 2018 / 5:14 AM / 24 days ago

BRIEF-Novimmune ‍Submits Biologics License Application In US For Its Lead Drug Emapalumab​

March 29 (Reuters) - NOVIMMUNE SA (IPO-NOVI.S):

* ‍SUBMITS BIOLOGICS LICENSE APPLICATION IN US FOR ITS LEAD DRUG EMAPALUMAB​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below